Novo Nordisk A/S’s blockbuster weight loss drug Wegovy is not remotely cost effective when compared to other weight-loss drugs for teens, a new study suggests.

Researchers from Columbia University modeled 100,000 adolescent patients with obesity to determine the cost-effectiveness of different weight-loss drugs. While Wegovy helped teenage patients lose the most weight, its $1,349 monthly cost made it a less appealing option than older, cheaper drugs, according to findings published Thursday in JAMA Network Open.

ncG1vNJzZmivp6x7o7jOqKSbnaKce6S7zGilnq%2BjZK6zwMico56rX2d9c3%2BMaW9ma2FkxKazzq%2BwZqGjYrmmrdKtZJyno6l6prLFnpqtoaaaerWxxKdksJ2ZnLW1ecuoqqxllKfCqHnIp2SsrKWZxg%3D%3D